

There is a clear indication that Capomulin is a viable drug regimen for tumor growth reduction. Capomulin and Remicane were the 2 drugs with the greatest number of mice completing the trial, all others observed deaths across the duration of the study. The correlation is very strong between mouse weight and tumor volume, indicating that weight might be a contributing factor to the effectiveness of any drug regimen for these purposes. There was one potential outlier within the Infubinol regimen. While most mice showed tumor volume increase, there was one mouse that had a reduction in tumor growth in the study.